HRP20100662T1 - Peptidi za desenzibilizaciju protiv alergena - Google Patents
Peptidi za desenzibilizaciju protiv alergena Download PDFInfo
- Publication number
- HRP20100662T1 HRP20100662T1 HR20100662T HRP20100662T HRP20100662T1 HR P20100662 T1 HRP20100662 T1 HR P20100662T1 HR 20100662 T HR20100662 T HR 20100662T HR P20100662 T HRP20100662 T HR P20100662T HR P20100662 T1 HRP20100662 T1 HR P20100662T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide
- composition
- sequence
- amino acids
- polypeptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 42
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 34
- 239000013566 allergen Substances 0.000 title claims 4
- 239000000203 mixture Substances 0.000 claims abstract 21
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract 5
- 208000026935 allergic disease Diseases 0.000 claims abstract 5
- 230000007815 allergy Effects 0.000 claims abstract 5
- 241000238711 Pyroglyphidae Species 0.000 claims abstract 2
- 229940046533 house dust mites Drugs 0.000 claims abstract 2
- 229920001184 polypeptide Polymers 0.000 claims 29
- 210000001744 T-lymphocyte Anatomy 0.000 claims 14
- 235000001014 amino acid Nutrition 0.000 claims 14
- 229940024606 amino acid Drugs 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 14
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 239000000428 dust Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical group CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- AGBSXNCBIWWLHD-FQEVSTJZSA-N siremadlin Chemical compound COC1=NC(OC)=NC=C1C(N1C(C)C)=NC2=C1[C@H](C=1C=CC(Cl)=CC=1)N(C=1C(N(C)C=C(Cl)C=1)=O)C2=O AGBSXNCBIWWLHD-FQEVSTJZSA-N 0.000 claims 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 1
- JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 claims 1
- 208000035533 House dust allergy Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 229960004784 allergens Drugs 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 108010047857 aspartylglycine Proteins 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 229940043131 pyroglutamate Drugs 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Sastav za uporabu u prevenciji ili lijecenju alergije na grinje iz kucne prasine po toleranciji, naznacen time, sto sadrzi: (i) polipeptid od HDM203B DLRQMRTVTPIRMQGGSGS, ili (ii) varijanta polipeptida u skladu sa (i), pri cemu navedena varijanta je polipeptid duljine 9 do 30 aminokiselina obuhvacajuci regiju koju cine: - sekvenca od (i) ili- sekvenca koja ima najmanje 70% homologije na sekvencu od (i), te koja je sposobna na toleranciju pojedinca na sekvencu od (i), ili (iii) varijanta polipeptida u skladu sa (i), pri cemu navedena varijanta je polipeptid duljine 9 do 30 aminokiselina obuhvacajuci regiju koju cine sekvenca koja predstavlja bilo: - fragment sekvence od (i) ili- homologni fragment sekvence od (i), sekvenca je sposobna na toleranciju pojedinca na sekvencu od (i) i ima duljinu od najmanje 9 aminokiselina, pri cemu navedeni homologni ima najmanje 70% homologije na bilo kojih 9 dodirnih aminokiselina u sekvenci od (i). Patent sadrzi jos 14 patentnih zahtjeva.
Claims (15)
1. Sastav za uporabu u prevenciji ili liječenju alergije na grinje iz kućne prašine po toleranciji, naznačen time, što sadrži:
(i) polipeptid od HDM203B DLRQMRTVTPIRMQGGSGS, ili
(ii) varijanta polipeptida u skladu sa (i), pri čemu navedena varijanta je polipeptid duljine 9 do 30 aminokiselina obuhvaćajući regiju koju čine:
- sekvenca od (i) ili
- sekvenca koja ima najmanje 70% homologije na sekvencu od (i), te koja je sposobna na toleranciju pojedinca na sekvencu od (i), ili
(iii) varijanta polipeptida u skladu sa (i), pri čemu navedena varijanta je polipeptid duljine 9 do 30 aminokiselina obuhvaćajući regiju koju čine sekvenca koja predstavlja bilo:
- fragment sekvence od (i) ili
- homologni fragment sekvence od (i),
sekvenca je sposobna na toleranciju pojedinca na sekvencu od (i) i ima duljinu od najmanje 9 aminokiselina, pri čemu navedeni homologni ima najmanje 70% homologije na bilo kojih 9 dodirnih aminokiselina u sekvenci od (i).
2. Sastav u skladu sa zahtjevom 1, naznačen time, što se dodatno sastoji od polipeptida HDM201 ESVKYVQSNGGAI, HDM205 SYYRYVAREQS, HDM03W ELVDSASQHG, ili njihove varijante kao što je definirano u zahtjevu 1 (ii) ili (iii).
3. Sastav u skladu sa zahtjevom 1 ili 2, naznačen time, što se sastoji od polipeptida:
[image]
ili njihove varijante kao što je definirano u zahtjevu 1 (ii) ili (iii).
4. Sastav kao što je definirano u zahtjevu 2 ili 3, naznačen time, što je ostatak glutamata prisutan na N kraju polipeptida od HDM201 ESVKYVQSNGGAI i / ili HDM03W ELVDSASQHG zamijenjen sa piroglutamatom.
5. Sastav u skladu sa bilo kojim prethodnim zahtjevom, naznačen time, što sastav:
a) je sposoban za toleranciju najmanje 50% ili najmanje 60% panela grinja iz prašine alergijskih pojedinaca u populaciji; i / ili
b) obuhvaća barem jedan daljnji polipeptid sve do ukupno trinaest jedinstvenih / različitih polipeptida, pri čemu dodatni polipeptidi:
- obuhvaćaju sekvencu koja ima najmanje 70% identiteta sekvence na najmanje 9 ili više dodirnih aminokiselina u bilo kojoj od SEQ ID NO: 1 do 104 kao što je prikazano u tablicama 4 do 6 i 8, koje nisu među već odabranim polipeptidima, i
- su 9 do 30, 9 do 20 ili 13 do 17 aminokiselina u duljini, i/ili
c) obuhvaća sve do najviše trinaest polipeptida.
6. Sastav u skladu sa bilo kojim prethodnim zahtjevom, naznačen time, što jedan ili više polipeptida ima jednu ili više modifikacija odabranih iz slijedećeg:
(i) N terminalna acetilacija;
(ii) C terminalna amidacija;
(iii) jedan ili više vodika na strani lanca amina od Arginina i/ili Lizina zamijenjenih sa metilen grupom;
(iv) glikozilacija, i
(v) fosforilaciju.
7. Sastav u skladu sa bilo kojim prethodnim zahtjevom, naznačen time, što je barem jedan od peptida projektiran da bude topljiv takav da sadrži:
i) N terminal do ostataka peptida koji bok je epitop T stanice: jedan do šest dodirnih aminokiselina odgovaraju dve do šest dodirnih aminokiselina neposredno N terminalu do navedenim ostacima u sekvenci proteina iz kojih proizlazi peptid, i / ili
ii) C terminal do ostataka peptida koji bok je epitop T stanice: jedan do šest dodirnih aminokiselina odgovaraju jednoj do šest dodirnih aminokiselina neposredno C terminalu do navedenim ostacima u sekvenci proteina iz kojih proizlazi peptid, ili
iii) oba N i C terminal do ostataka peptida koji bok je epitop T stanice, barem jednu amino kiselinu odabranu iz arginina, lizina, histidina, glutamata i aspartata, pri čemu polipeptid ima topljivost od najmanje 3.5mg/ml i T stanica epitopa ima topljivost manju od 3.5mg/ml, i/ili pri čemu barem jedan od peptida je projektiran da bude topljiv takav da:
iv) bilo koji ostaci cisteina u izvornoj sekvenci peptida su zamijenjeni sa serinom ili 2-aminobuternom kiselinom i/ili
v) svaki hidrofobni ostaci sve do tri aminokiseline kod N ili C krajeve od izvorne sekvence peptida, koji nisu sadržani u T stanici epitopa brišu se, i / ili
vi) bilo koje dvije uzastopne aminokiseline koje sadrže sekvencu Asp-u Gly sve do četiri aminokiseline kod N ili C krajeva od izvorne sekvence peptida, koji nisu sadržani u T stanici epitopa brišu se.
8. Sastav u skladu sa bilo kojim prethodnim zahtjevom, naznačen time, što svaki polipeptid ima koncentraciju u rasponu od 0.03 do 200 nmol/ml, 0.3 do 200 nmol/ml ili 30 do 120 nmol/ml.
9. Sastav ili vektor za uporabu u prevenciji ili liječenju alergije na grinje iz prašine po toleranciji, naznačen time, što u položaju bilo kojeg polipeptida definiranog u zahtjevima 1 do 5 je polinukleotid sposoban izraziti navedeni polipeptid, opcionalno pri čemu sastav ili vektor sadrži između četiri i trinaest različitih sekvenci polinukleotida koje svaka kodira različite polipeptide.
10. Proizvod koji sadrži između četiri i trinaest polipeptida uključujući i polipeptid sastava zahtjeva 1, naznačen time, što je svaki različiti polipeptid simultano, odvojeno ili sekvencijski uporabljen u prevenciji ili liječenju alergije na grinje iz kućne prašine po toleranciji, opcionalno pri čemu proizvod dodatno uključuje polipeptide sastava bilo kojeg zahtjeva 2-5.
11. Polipeptid, naznačen time, što je od HDM203B DLRQMRTVTPIRMQGGSGS, ili njegove varijante kao što je definirano u zahtjevu 1 (ii) ili (iii).
12. Farmaceutska formulacija, naznačena time, što za uporabu u prevenciji ili liječenju alergije na grinje iz prašine po toleranciji se sastoji od sastava ili vektora u skladu sa bilo kojim zahtjevom 1 do 9; ili proizvoda u skladu sa zahtjevom 10; i farmaceutski prihvatljivih nositelja ili otapala, opcionalno pri čemu je sastav, vektor ili proizvod formuliran za oralnu primjenu, nosnu primjenu, epikutanu primjenu, potkožnu primjenu, sublingvalnu primjenu, intradermalnu primjenu, bukalnu primjenu ili za primjenu udisanjem ili injektiranjem
13. Sastav kao što je definirano u bilo kojem zahtjevom 1 do 9, ili proizvod kao što je definirano u zahtjevu 10, naznačeni time, što se dodatno sastoje od daljnjeg alergena polipeptida za uporabu u toleranciji pojedinca do daljnjeg alergena polipeptida.
14. In vitro metoda, naznačena time, što se utvrđivanje da li T stanice prepoznaju polipeptid kao što je definirano u zahtjevu 1 sastoji od kontaktiranja navedenih T stanica sa navedenim polipeptidom i utvrđivanja da li su T stanice stimulirane od navedenih polipeptida.
15. In vitro metodu utvrđivanja da li pojedinac ima ili je u opasnosti od stanja u kojem je, naznačena time, što je stanje karakterizirano sa alergijskim simptomima kao odgovor na alergene grinja iz kućne prašine, metoda se sastoji od testiranje da li pojedinac ima T stanice koje reagiraju na sastav kao što je definirano u bilo kojem od zahtjeva 1 do 9, čime bi se utvrdilo da li pojedinac ima ili je u opasnosti od stanja, opcionalno odgovor T-stanice sa navedenim sastavom je mjeren pomoću kontaktiranja sastava sa T stanicama u uzorku izabranom iz predmeta, pod uvjetima koji omogućuju sastav i T stanice na interakciju, te utvrđivanje da li je ili nije bilo koji od T stanica stimuliran i čime bi se utvrdilo da li je ili nije imunološki odgovor T-stanice prisutan ili odsutan
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0715949A GB0715949D0 (en) | 2007-08-15 | 2007-08-15 | Peptide with improved solubility |
| GB0716224A GB0716224D0 (en) | 2007-08-20 | 2007-08-20 | Peptides for vaccine |
| GB0723337A GB0723337D0 (en) | 2007-11-28 | 2007-11-28 | Peptide with reduced dimer formation |
| PCT/GB2008/002780 WO2009022156A2 (en) | 2007-08-15 | 2008-08-15 | Peptides for desensibilization against allergens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100662T1 true HRP20100662T1 (hr) | 2011-01-31 |
Family
ID=40134075
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100662T HRP20100662T1 (hr) | 2007-08-15 | 2010-12-01 | Peptidi za desenzibilizaciju protiv alergena |
| HRP20130270AT HRP20130270T1 (hr) | 2007-08-15 | 2013-03-25 | Peptid s reduciranom formacijom dimera |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130270AT HRP20130270T1 (hr) | 2007-08-15 | 2013-03-25 | Peptid s reduciranom formacijom dimera |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US8652485B2 (hr) |
| EP (4) | EP2083856B1 (hr) |
| JP (3) | JP5697447B2 (hr) |
| KR (1) | KR101699554B1 (hr) |
| CN (2) | CN101820907B (hr) |
| AT (1) | ATE482721T1 (hr) |
| AU (1) | AU2008288283B2 (hr) |
| BR (1) | BRPI0815395A2 (hr) |
| CA (1) | CA2696563A1 (hr) |
| CY (2) | CY1110981T1 (hr) |
| DE (1) | DE602008002810D1 (hr) |
| DK (2) | DK2083856T3 (hr) |
| EA (2) | EA018110B1 (hr) |
| ES (1) | ES2402956T3 (hr) |
| HK (2) | HK1132194A1 (hr) |
| HR (2) | HRP20100662T1 (hr) |
| IL (1) | IL203943A (hr) |
| MX (1) | MX2010001779A (hr) |
| NZ (2) | NZ583362A (hr) |
| PL (1) | PL2083856T3 (hr) |
| PT (2) | PT2083856E (hr) |
| SI (2) | SI2190473T1 (hr) |
| WO (4) | WO2009022156A2 (hr) |
| ZA (2) | ZA201001056B (hr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| CN101820907B (zh) * | 2007-08-15 | 2013-05-01 | 切尔卡西亚有限公司 | 针对过敏原去敏化的肽 |
| EP2331124A1 (en) * | 2008-08-15 | 2011-06-15 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of il-10 production |
| SI2153841T2 (sl) | 2008-08-15 | 2016-02-29 | Circassia Limited | Cepivo, ki obsega peptide Amb a 1, za uporabo pri zdravljenju alergije na ambrozijo |
| GB0821806D0 (en) | 2008-11-28 | 2009-01-07 | Circassia Ltd | Compositions with reduced dimer formation |
| NZ594268A (en) | 2009-02-05 | 2013-05-31 | Circassia Ltd | Grass peptides for vaccine |
| EP2486940B1 (en) * | 2009-10-08 | 2017-10-04 | Aeon Medix Inc. | Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof |
| US9975932B2 (en) | 2010-01-14 | 2018-05-22 | Merck Patent Gmbh | Variants of group 5 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues |
| GB201002559D0 (en) * | 2010-02-15 | 2010-03-31 | Circassia Ltd | Birch peptides for vaccine |
| EP3662916A1 (en) * | 2010-06-03 | 2020-06-10 | ALK-Abelló A/S | Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof |
| ES2561825T3 (es) * | 2010-09-24 | 2016-03-01 | María R. Díaz-Torres | Péptidos |
| EP2460824A1 (en) * | 2010-12-01 | 2012-06-06 | Biomay Ag | Hypoallergenic polypeptides for the treatment of house dust mite allergy |
| EA027410B1 (ru) | 2011-04-29 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Наноносители, вызывающие иммунную толерантность, для снижения ответной реакции цитотоксических t-лимфоцитов |
| CN103748105A (zh) * | 2011-06-15 | 2014-04-23 | 生物技术工具公司 | 一种生产水解过敏原的方法 |
| WO2013019658A2 (en) | 2011-07-29 | 2013-02-07 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
| GB201208293D0 (en) | 2012-05-11 | 2012-06-20 | Circassia Ltd | Hydrochlorice salt of peptide |
| GB201209868D0 (en) * | 2012-06-01 | 2012-07-18 | Circassia Ltd | Alternaria peptides |
| GB201209862D0 (en) | 2012-06-01 | 2012-07-18 | Circassia Ltd | Cladosporium peptides |
| WO2014066939A1 (en) | 2012-10-30 | 2014-05-08 | Monash University | Novel immunotherapeutic molecules and uses thereof |
| CN105338968A (zh) | 2013-05-03 | 2016-02-17 | 西莱克塔生物科技公司 | 降低或预防响应于非变应原性抗原的过敏反应的致耐受性合成纳米载体 |
| WO2014195382A1 (en) * | 2013-06-05 | 2014-12-11 | Alergenetica Sl | T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy |
| DK3003366T3 (da) * | 2013-06-06 | 2020-10-26 | Anergis S A | På hinanden følgende overlappende peptider til behandling af allergi overfor husstøvmider |
| RU2689552C2 (ru) * | 2013-09-25 | 2019-05-28 | Аравакс Пти Лтд | Новая иммунотерапевтическая композиция и ее применения |
| WO2015100360A1 (en) * | 2013-12-23 | 2015-07-02 | Alk-Abelló A/S | Peptide combinations and uses thereof in treating dust mite allergy |
| CN106132996B (zh) | 2014-03-31 | 2020-10-09 | 勃林格殷格翰动物保健有限公司 | 经改良的模块化抗原转运分子及其用途 |
| CA2957737A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
| US10166286B2 (en) | 2015-02-20 | 2019-01-01 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| US11452774B2 (en) | 2015-02-20 | 2022-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| US10143742B2 (en) | 2015-02-20 | 2018-12-04 | The Board Of Trustees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| US10149904B2 (en) | 2015-02-20 | 2018-12-11 | The Board Of Trusteees Of The Leland Stanford Junior University | Mixed allergen compositions and methods for using the same |
| EP3279218A4 (en) * | 2015-03-30 | 2018-12-05 | Osaka University | Immunizing peptide, method for producing immunizing peptide, pharmaceutical composition for immune disorders containing same, and method for treating immune disorders |
| US10898568B2 (en) | 2015-09-30 | 2021-01-26 | Boehringer Ingelheim Vetmedica Gmbh | Modular antigen transportation molecules and uses thereof in animals |
| KR101858840B1 (ko) | 2016-01-15 | 2018-05-16 | 단국대학교 천안캠퍼스 산학협력단 | 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제 |
| BR112019018748A2 (pt) | 2017-03-11 | 2020-04-07 | Selecta Biosciences Inc | métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor |
| EP3654778A1 (en) | 2017-07-18 | 2020-05-27 | Before Brands, Inc. | Methods for making mixed allergen compositions |
| US10596270B2 (en) * | 2017-09-18 | 2020-03-24 | Sutro Biopharma, Inc. | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates |
| CN108078891B (zh) * | 2017-12-28 | 2021-05-07 | 昆明赛诺制药股份有限公司 | 一种含美洲大蠊精提物的保湿修复洗面奶 |
| CN107970199B (zh) * | 2018-01-03 | 2021-05-07 | 昆明赛诺制药股份有限公司 | 一种含美洲大蠊精提物的牙膏 |
| WO2020154476A1 (en) | 2019-01-23 | 2020-07-30 | Before Brands, Inc. | Methods for making mixed allergen compositions |
| CN117362453B (zh) * | 2023-12-08 | 2024-02-27 | 山东硕景生物科技有限公司 | 一种Derf1重组抗原、其制备方法及应用 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0044532B1 (en) | 1980-07-18 | 1986-04-23 | E.I. Du Pont De Nemours And Company | Monothioglycerol as thiol-protector in lyophilized materials |
| US4442212A (en) | 1980-11-10 | 1984-04-10 | E. I. Du Pont De Nemours & Company | Monothioglycerol as thiol-protector in lyophilized materials |
| US5126399A (en) * | 1986-04-30 | 1992-06-30 | Board Of Regents, The University Of Texas System | Methods and compositions for the preparation and use of site-directed immunologic reagents |
| US4906564A (en) * | 1987-03-13 | 1990-03-06 | The United States Of America As Represented By The Secretary Of The Army | Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens |
| EP0362290A4 (en) * | 1987-06-17 | 1991-09-25 | Princess Margaret Children's Medical Research Foundation (Inc.) | Cloning of mite allergens |
| FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
| GB8812214D0 (en) * | 1988-05-24 | 1988-06-29 | Hoffmann La Roche | Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope |
| ES2013359A6 (es) | 1988-11-04 | 1990-05-01 | Corporacion Biolog Farmaceutic | Procedimiento para la fabricacion de alergenos inmunogenicos polimerizados. |
| CA1340977C (en) | 1988-11-15 | 2000-04-25 | Monty Krieger | Scavenger receptor protein and antibody thereto |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US6019972A (en) | 1989-11-03 | 2000-02-01 | Immulogic Pharmaceutical Corporation | Peptides of human T cell reactive feline protein (TRFP) |
| US5547669A (en) * | 1989-11-03 | 1996-08-20 | Immulogic Pharma Corp | Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I |
| DK0500785T3 (da) | 1989-11-03 | 2002-08-19 | Immulogic Pharma Corp | Humant T-celleaktivitet felint protein (TRFP) isoleret fra husstøv samt anvendelser heraf |
| US5433948A (en) * | 1990-02-13 | 1995-07-18 | Thomas; Wayne R. | Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
| CA2091449C (en) * | 1990-09-11 | 2002-11-05 | Wayne R. Thomas | Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
| US5593698A (en) | 1990-10-31 | 1997-01-14 | Autoimmune, Inc. | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides |
| JP2632603B2 (ja) | 1991-03-12 | 1997-07-23 | アサヒビール株式会社 | ヒト抗ＤｅｒｆＩＩＩｇＥ抗体が結合するペプチド |
| US6982326B1 (en) * | 1991-07-12 | 2006-01-03 | Immulogic Pharmaceutical Corporation | Allergenic proteins and peptides from Japanese cedar pollen |
| US6555116B1 (en) | 1991-10-12 | 2003-04-29 | Regents Of The University Of California | Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin |
| DE69233772D1 (de) | 1991-10-16 | 2009-11-12 | Merck Patent Gmbh | T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe) |
| US7288256B1 (en) * | 1991-10-16 | 2007-10-30 | Merck Patent Gmbh | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| WO1994024281A1 (en) | 1993-04-14 | 1994-10-27 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| US6696061B1 (en) | 1992-08-11 | 2004-02-24 | President And Fellows Of Harvard College | Immunomodulatory peptides |
| AU664920B2 (en) | 1992-08-14 | 1995-12-07 | Asahi Breweries, Ltd. | Peptide having allergenicity |
| CA2152818A1 (en) * | 1992-12-31 | 1994-07-21 | Jay P. Morgenstern | Allergenic proteins and peptides from dog dander and uses therefor |
| US5697103A (en) | 1993-01-11 | 1997-12-16 | Personal Expression I, Inc. | Therapeutic glove |
| EP0688338A1 (en) | 1993-03-12 | 1995-12-27 | Immulogic Pharmaceutical Corporation | T cell epitopes of ryegrass pollen allergen |
| US6849427B1 (en) * | 1993-03-12 | 2005-02-01 | Immulogic Pharmaceutical Corp. | Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor |
| JPH09501043A (ja) * | 1993-04-14 | 1997-02-04 | イミュロジク ファーマスーティカル コーポレイション | Ｄｅｒｍａｔｏｐｈａｇｏｉｄｅｓ（室内塵ダニ）由来の主要アレルゲンのｔ細胞エピトープ |
| WO1994027634A1 (en) | 1993-06-02 | 1994-12-08 | Institute For Child Health Research | Cryptic peptides for use in inducing immunologic tolerance |
| JPH09504167A (ja) | 1993-08-13 | 1997-04-28 | イミュロジック ファーマスーティカル コーポレイション | ドクムギ花粉アレルゲンのｔ細胞エピトープ |
| US6180771B1 (en) * | 1993-12-08 | 2001-01-30 | Immulogic Pharmaceutical Corp. | Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor |
| JPH07215996A (ja) | 1994-01-31 | 1995-08-15 | Torii Yakuhin Kk | ダニアレルゲンのｂ細胞エピトープ |
| US5820862A (en) | 1994-04-14 | 1998-10-13 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| KR100379161B1 (ko) * | 1994-04-14 | 2003-06-11 | 이뮤로직 파마시티컬 코포레이션 | 집먼지진드기에의한알레르기를치료하기위한의학적펩티드조성물 |
| US6759234B1 (en) * | 1994-09-02 | 2004-07-06 | Immulogic Pharmaceutical Corporation | Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response |
| IL115744A (en) | 1994-10-27 | 2000-07-16 | Akzo Nobel Nv | Peptides comprising a subsequence of human cartilage glycoprotein - 39 |
| DE19508192A1 (de) | 1995-03-09 | 1996-09-12 | Behringwerke Ag | Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung |
| DE19545662C2 (de) * | 1995-12-07 | 1998-11-26 | Mannesmann Sachs Ag | Selbstpumpendes hydropneumatisches Federbein mit innerer Niveauregulierung |
| US6737406B1 (en) | 1996-03-21 | 2004-05-18 | Circassia, Ltd. | Cryptic peptides and method for their identification |
| US6238888B1 (en) | 1997-12-22 | 2001-05-29 | Human Genone Sciences, Inc. | Keratinocyte growth factor-2 formulations |
| WO1999034826A1 (en) | 1998-01-09 | 1999-07-15 | Circassia Limited | Methods and compositions for desensitisation |
| FR2806727A1 (fr) * | 2000-03-23 | 2001-09-28 | Pf Medicament | Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable |
| HU229377B1 (hu) | 2000-08-21 | 2013-11-28 | Apitope Technology Bristol Ltd | Tolerogén humán peptidek |
| WO2002017956A2 (en) | 2000-08-31 | 2002-03-07 | Chiron Corporation | Stabilized fgf formulations containing reducing agents |
| MXPA03004174A (es) * | 2000-11-16 | 2004-12-02 | Alk Abello As | Alergenos mutantes novedosos. |
| US7786257B2 (en) * | 2000-12-18 | 2010-08-31 | University Of Kansas | Signal-1/signal-2 bifunctional peptide inhibitors |
| US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| FR2820425B1 (fr) | 2001-02-08 | 2004-01-02 | Commissariat Energie Atomique | Melange de peptides issus d'une proteine nef et leurs applications |
| JP4812951B2 (ja) * | 2001-03-21 | 2011-11-09 | 一般財団法人化学及血清療法研究所 | 特異性不明のｔ細胞のクローン化法及びその認識ペプチドリガンドの同定方法 |
| GB0108752D0 (en) | 2001-04-06 | 2001-05-30 | Isis Innovation | Peptide epitopes and uses thereof |
| AU2002305138A1 (en) | 2001-04-09 | 2002-10-21 | Mayo Foundation For Medical Education And Research | Methods and materials for cancer treatment |
| AUPR775401A0 (en) * | 2001-09-18 | 2001-10-11 | Monash University | Novel Epitopes and Uses Thereof |
| DE60237841D1 (de) | 2001-11-13 | 2010-11-11 | Genentech Inc | Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung |
| EP1453539B1 (en) | 2001-12-05 | 2008-11-19 | Circassia Limited | Immunotherapeutic methods and systems |
| AUPS148202A0 (en) | 2002-04-02 | 2002-05-09 | Monash University | Immunotherapeutic and immunoprophylactic reagents |
| FR2841906B1 (fr) * | 2002-07-05 | 2006-08-18 | Stallergenes Sa | Molecule d'acide nucleique codant une preproproteine d'allergene d'un acarien du genre dermatophagoides ou euroglyphus et son utilisation pour la production dudit allergene dans les plantes |
| RU2324704C2 (ru) | 2002-07-17 | 2008-05-20 | Цитос Байотекнолоджи Аг | Молекулярные массивы антигенов |
| US20040071718A1 (en) | 2002-09-18 | 2004-04-15 | Jaw-Ji Tsai | Local nasal immunotherapy for allergen-induced airway inflammation |
| US8198401B2 (en) | 2003-03-07 | 2012-06-12 | London Health Sciences Centre Research Inc. | Peptides associated with HLA-DR MHC class II molecule and involved in rheumatoid arthritis |
| WO2005000891A2 (en) | 2003-06-26 | 2005-01-06 | Merck Patent Gmbh | Thrombopoietin proteins with improved properties |
| GB0315754D0 (en) * | 2003-07-04 | 2003-08-13 | Univ Aberdeen | Pharmaceutical compositions |
| US20050053615A1 (en) * | 2003-07-16 | 2005-03-10 | Best Elaine A. | Variants of mite group 1 allergens for the treatment of house dust mite allergy |
| EP1685160A1 (en) | 2003-11-10 | 2006-08-02 | Arriva-Prometic Inc. | Dry recombinant human alpha 1-antitrypsin formulation |
| WO2005103082A2 (en) | 2004-04-23 | 2005-11-03 | Novozymes A/S | Group 1 mite polypeptide variants |
| WO2005121166A1 (en) * | 2004-06-10 | 2005-12-22 | Monash University | Novel immunointeractive molecules and uses thereof |
| US20060029551A1 (en) | 2004-08-05 | 2006-02-09 | Kui Liu | Stable particle formulations of erythropoietin receptor agonists |
| CN101044244B (zh) | 2004-09-27 | 2010-05-05 | 株式会社林原生物化学研究所 | 异环麦芽寡糖和异环麦芽寡糖合酶以及其制备方法和用途 |
| EP1843779A2 (en) | 2005-02-01 | 2007-10-17 | Attenuon, LLC | Compositions containing the anti-angiogenic phscn-peptide |
| FR2881746B1 (fr) | 2005-02-07 | 2007-04-13 | Centre Nat Rech Scient | Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications |
| JP2009508118A (ja) | 2005-09-15 | 2009-02-26 | アルク−アベッロ エイ／エス | アレルゲンの定量方法 |
| EP1829895A1 (en) | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| GB0609121D0 (en) | 2006-05-09 | 2006-06-21 | Univ Birmingham | Peptide Therapy |
| AT503690A1 (de) | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| PT2476435T (pt) * | 2006-08-11 | 2018-03-05 | Life Sciences Res Partners Vzw | Péptidos imunogénicos e a sua utilização em distúrbios imunitários |
| EP1958645A1 (en) | 2007-02-13 | 2008-08-20 | Biomay AG | Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof |
| US8148105B2 (en) | 2007-03-16 | 2012-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Scaleable manufacturing process for cysteine endoprotease B, isoform 2 |
| GB0710529D0 (en) * | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| CN101820907B (zh) * | 2007-08-15 | 2013-05-01 | 切尔卡西亚有限公司 | 针对过敏原去敏化的肽 |
| WO2009067191A2 (en) * | 2007-11-16 | 2009-05-28 | The General Hospital Corporation | Methods and compositions for the treatment of hepatitis c virus (hcv) infection |
| GB2455108A (en) * | 2007-11-28 | 2009-06-03 | Circassia Ltd | T-Cell dependent method for detecting non-allergic or intrinsic disorders |
-
2008
- 2008-08-15 CN CN2008801116120A patent/CN101820907B/zh not_active Expired - Fee Related
- 2008-08-15 DE DE602008002810T patent/DE602008002810D1/de active Active
- 2008-08-15 AT AT08788348T patent/ATE482721T1/de active
- 2008-08-15 PL PL08788348T patent/PL2083856T3/pl unknown
- 2008-08-15 AU AU2008288283A patent/AU2008288283B2/en not_active Ceased
- 2008-08-15 EA EA201070270A patent/EA018110B1/ru not_active IP Right Cessation
- 2008-08-15 EP EP08788348A patent/EP2083856B1/en active Active
- 2008-08-15 DK DK08788348.4T patent/DK2083856T3/da active
- 2008-08-15 ES ES08788347T patent/ES2402956T3/es active Active
- 2008-08-15 EP EP10006685A patent/EP2286833A3/en not_active Withdrawn
- 2008-08-15 SI SI200830933T patent/SI2190473T1/sl unknown
- 2008-08-15 WO PCT/GB2008/002780 patent/WO2009022156A2/en active Application Filing
- 2008-08-15 US US12/673,412 patent/US8652485B2/en active Active
- 2008-08-15 SI SI200830119T patent/SI2083856T1/sl unknown
- 2008-08-15 EA EA201070271A patent/EA023303B1/ru not_active IP Right Cessation
- 2008-08-15 US US12/673,386 patent/US9340580B2/en not_active Expired - Fee Related
- 2008-08-15 US US12/673,334 patent/US8551493B2/en active Active
- 2008-08-15 CA CA2696563A patent/CA2696563A1/en not_active Abandoned
- 2008-08-15 CN CN201310140326.XA patent/CN103272227B/zh not_active Expired - Fee Related
- 2008-08-15 WO PCT/GB2008/002778 patent/WO2009022154A2/en active Application Filing
- 2008-08-15 EP EP08788347A patent/EP2190473B1/en not_active Revoked
- 2008-08-15 KR KR1020107005503A patent/KR101699554B1/ko active IP Right Grant
- 2008-08-15 MX MX2010001779A patent/MX2010001779A/es active IP Right Grant
- 2008-08-15 PT PT08788348T patent/PT2083856E/pt unknown
- 2008-08-15 PT PT111781811T patent/PT2397154E/pt unknown
- 2008-08-15 NZ NZ583362A patent/NZ583362A/en not_active IP Right Cessation
- 2008-08-15 NZ NZ583361A patent/NZ583361A/xx not_active IP Right Cessation
- 2008-08-15 DK DK08788347.6T patent/DK2190473T3/da active
- 2008-08-15 WO PCT/GB2008/002779 patent/WO2009022155A2/en active Application Filing
- 2008-08-15 EP EP11178181.1A patent/EP2397154B1/en active Active
- 2008-08-15 JP JP2010520628A patent/JP5697447B2/ja not_active Expired - Fee Related
- 2008-08-15 WO PCT/GB2008/002781 patent/WO2009022157A2/en active Application Filing
- 2008-08-15 BR BRPI0815395-7A2A patent/BRPI0815395A2/pt not_active IP Right Cessation
-
2009
- 2009-12-24 HK HK09112173.5A patent/HK1132194A1/xx not_active IP Right Cessation
-
2010
- 2010-02-12 ZA ZA2010/01056A patent/ZA201001056B/en unknown
- 2010-02-12 ZA ZA2010/01054A patent/ZA201001054B/en unknown
- 2010-02-14 IL IL203943A patent/IL203943A/en not_active IP Right Cessation
- 2010-12-01 HR HR20100662T patent/HRP20100662T1/hr unknown
- 2010-12-07 CY CY20101101127T patent/CY1110981T1/el unknown
-
2012
- 2012-06-01 HK HK12105353.6A patent/HK1164700A1/xx not_active IP Right Cessation
-
2013
- 2013-03-25 HR HRP20130270AT patent/HRP20130270T1/hr unknown
- 2013-08-23 US US13/974,603 patent/US20130336999A1/en not_active Abandoned
-
2014
- 2014-01-08 US US14/150,045 patent/US20140186403A1/en not_active Abandoned
- 2014-10-03 JP JP2014204979A patent/JP6040207B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-07 CY CY20151100901T patent/CY1116828T1/el unknown
-
2016
- 2016-04-11 US US15/095,480 patent/US20160289281A1/en not_active Abandoned
- 2016-09-29 JP JP2016191563A patent/JP2017061455A/ja active Pending
- 2016-10-17 US US15/294,973 patent/US9744222B2/en active Active - Reinstated
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100662T1 (hr) | Peptidi za desenzibilizaciju protiv alergena | |
| JP2010536333A5 (hr) | ||
| HRP20120206T4 (hr) | Cjepivo koje sadrži amb a 1 peptide za uporabu u lijeäśenju alergije na ambroziju | |
| HRP20100644T1 (hr) | Cijepivo kombinacije peptida protiv alergije na macke | |
| AU2014232954B2 (en) | Hepcidin analogues and uses therof | |
| WO2007127977A3 (en) | Methods of evaluating peptide mixtures | |
| DE69333243D1 (de) | Mutierte polypeptide des interleukin-3(il-3) | |
| US10434134B2 (en) | Peptide treatment for inflammation and fibrosis | |
| KR20220075343A (ko) | 접합된 헵시딘 모방체 | |
| BRPI0515033A (pt) | processo para a obtenção de uma mistura de polipetìdeos de trifluoroacetila, produto de trifluoroacetila, composição, mistura de polipetìdeos de trifluoroacetila, e, processos para a obtenção de uma composição farmacêutica, para a produção de acetato de glatirámero e para a análise da percentagem de tirosina bromada em uma amostra de acetato de glatirámero | |
| DK2162462T3 (da) | Cxc-chemokin-receptor-4 (cxcr4) antagonistisk polypeptid | |
| EP0333356A3 (en) | Hirudin peptides | |
| US7485321B2 (en) | Peyer's patch and/or M-cell targeting ligands | |
| ATE544461T1 (de) | Rekonstituierte tenside mit verbesserten eigenschaften | |
| JP2012516693A5 (hr) | ||
| JP2012500194A5 (hr) | ||
| TW202304951A (zh) | 結合鐵調素模擬物 | |
| MX2020008902A (es) | Analogos de compstatina y sus usos medicos. | |
| CY1112839T1 (el) | Πεπτιδια χ-κωνοτοξινες που εχουν ενα αμινοτελικο πυρογλουταμικο οξυ | |
| AU6961601A (en) | Transport peptides among which c-terminal E<sup>rns</sup> peptide and analogues thereof | |
| ATE551353T1 (de) | Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten | |
| WO2004106366A8 (en) | Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines | |
| WO2007002233A3 (en) | Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau | |
| Yaguchi et al. | The Amino Acid Sequence of the N-Terminal Region of Some 30 S Ribosomal Proteins from Escherichia coli and Bacillus stearothermophilus: Homologies in Ribosomal Proteins | |
| TH86212B (th) | สูตรผสมเพื่อการรักษาของปัจจัยการเติบโตของคีราทิโนไซต์ |